Research Center of Clinical Pharmacy, First Affiliated Hospital Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Zhejiang Provincial Key Laboratory for Drug Evaluation & Clinical Research, Hangzhou, China.
Immunotherapy. 2020 Jun;12(8):555-561. doi: 10.2217/imt-2019-0100. Epub 2020 May 6.
Intrahepatic cholangiocarcinoma is a disease with grave prognosis due to limited therapeutic regimens. Programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitor have shown dramatic clinical effectiveness in multiple solid tumors. Here, we report the case that a patient with metastasis intrahepatic cholangiocarcinoma, being failure of first-line chemotherapy, was enrolled into the Phase I study of a PD-1 inhibitor, sintilimab. The patient achieved complete remission after three cycles of treatment with mild adverse reaction. In addition, the tumor mutational burden and the microsatellite instability status were low in the present case. Hence, PD-1 inhibitor might be a promising therapeutic approach for patients with advanced cholangiocarcinoma.
肝内胆管癌由于治疗方案有限，预后较差。程序性细胞死亡蛋白 1（PD-1）/程序性死亡配体 1（PD-L1）抑制剂在多种实体肿瘤中显示出显著的临床疗效。在这里，我们报告了一例转移性肝内胆管癌患者，一线化疗失败后入组 PD-1 抑制剂信迪利单抗的 I 期研究。该患者在三个周期的治疗后达到完全缓解，仅有轻微的不良反应。此外，本病例的肿瘤突变负荷和微卫星不稳定性状态较低。因此，PD-1 抑制剂可能是晚期胆管癌患者有希望的治疗方法。
